Vilotos Pharmaceuticals is a Maryland based pharmaceutical company specialized in developing novel drugs for the prevention and treatment of endemic and emerging viruses. The company is currently focused on developing therapies against coronaviruses, hepatitis C, HIV and several other viruses. The lead molecule of the company is being developed to combat the current coronavirus (COVID-19) pandemic.
The capacity of Vilotos to realize its mission is enhanced by strategic collaborations with private and public research centers of excellence including Harvard Medical School, National Institute for Allergy and Infectious Diseases (NIAID) at the US NIH and University of the West Indies. Vilotos continues to seek new private/public partnerships to expand the utilization and impact of its technologies.
Dr. Henry Lowe, PhD. ,Director and Chairman, was educated at University of the West Indies, (B.Sc. Hons.), University of Sydney, (M.Sc.), Manchester University, (Ph.D.), Bolton Institute of Technology England, (Dip. Technical Education), Harvard University and M.I.T, U.S.A., (Post Doctoral Studies). Dr. Lowe served as Permanent Secretary for the Government of Jamaica, Dr. Lowe researched and established the first Ministry of Science & Environment in the CARICOM region. He served as Chairman as well as President & CEO of Blue Cross of Jamaica (including the Caribbean Islands). Dr. Lowe holds many awards and accolades, including the Jamaica Observer Business Leader Award (2006) and the CCRP Living Legend Award (2012); and is the only Jamaican who is a member of the prestigious American Association for Cancer Research (AACR). Dr. Lowe is a member of the American Association for the Advancement of Science, Fellow, Royal Society of Medicine United Kingdom, Harvard Medical School Postgraduate Association, American Association of Pharmaceutical Scientists and the American Chemical Society and a Life Member of the New York Academy of Sciences. Dr. Lowe is an Adjunct Professor in the Department of Medicine, University of Maryland School of Medicine, USA and Distinguished Adjunct Professor of Ethno-medicinal Chemistry, University of Technology, Jamaica.
Mr. Swanson is Co-Founder and Executive Vice Chairman of Flavocure Biotech, Inc. a founding partner of the International Phytomedicines Institute at Harvard Medical School. A start-up veteran, Mr. Swanson has served as Co-Founder, President & Chief Executive Officer and Director of Blackline Safety Corp., a preeminent (Deloitte Fastest 500, TSX 50, Profit 500 & IDC Top 10 to Watch) technology company publicly traded on the Toronto Venture Exchange under the trading symbol: BLN. Under his leadership, he company grew to over 100 employees and a market capitalization of nearly $300,000,000. Prior to this, Mr. Swanson was a top revenue earner for several technology companies where he focused on life sciences at Amgen, DaVita, Pfizer and others.
Mr. Swanson holds a degree in Economics from Pepperdine University and a Masters in Business Administration from Graziadio School of Business & Management where he graduated with distinction. He is a guest lecturer at UCLA Anderson School of Management and Pepperdine Graziadio School of Business & Management.
Dr. Toyang has over 20 years of research experience in the field of medicinal plants and pharmacognosy at various research institutions including Heifer International, the National Center for Natural Products Research at the University of Mississippi School of Pharmacy, Natural Products Research Laboratory of the University of Leiden, The Netherlands and the Institute of Human Virology of the University of Maryland School of Medicine. He completed his PhD degree in Pharmacognosy under the supervision of Prof. Dr. Rob Verpoorte at the University of Leiden, The Netherlands. Dr. Toyang is the author of over 25 peer reviewed scientific publications and a holder of two patents and several pending patent applications.